Scientists, Doctors and Patients Join the ACLU in Calling on DEA to
Adopt the
Court’s Recommendation

WASHINGTON – The American Civil Liberties Union applauded a ruling issued by
a U.S. Drug Enforcement Administration judge that recommends ending the
federal government’s sixty-five year monopoly on the supply of marijuana
available for Food and Drug Administration-approved medical research.

The ACLU represents University of Massachusetts-Amherst Professor Lyle
Craker, who petitioned the Drug Enforcement Administration (DEA) for a license to grow research-grade marijuana for
use in privately-funded studies that aim to develop the plant into a legal,
prescription medicine. The DEA judge ruled that it is in the public interest to
end the federal National Institute on Drug Abuse (NIDA) monopoly on the supply
of marijuana that can be used in Food and Drug Administration (FDA)-approved research.

"For too long the DEA has inappropriately inserted politics into a regulatory
process that should be left to the FDA and medical science," said Allen Hopper,
an attorney with the ACLU Drug Law Reform Project. "We are pleased that the
judge has recommended an end to the federal government’s blockade of medical
marijuana research."

The DEA must now either accept or reject the court’s recommendation, and
scientists, doctors and medical marijuana patients nationwide joined the ACLU in
urging the agency to comply with the court’s finding and halt federal
obstruction of medical marijuana research.

"This ruling is a victory for science, medicine and the public good," said
Professor Craker. "I hope that the DEA abides by the decision and allows the work to go forward unimpeded by drug war politics."

The ruling issued yesterday by U.S. Department of Justice-appointed
Administrative Law Judge Mary Ellen Bittner marks a major step forward in the
six year struggle by Professor Craker to gain a DEA license to grow
research-grade marijuana for use by other scientists in privately funded,
government-approved studies.

Following nine days of hearings, testimony and evidence from both sides, including from
researchers who reported that the government denied their requests for
marijuana for use in FDA-approved research protocols, Judge Bittner concluded,
"that there is currently an inadequate supply of marijuana available for
research purposes…" and that, "Respondent’s registration to cultivate marijuana
would be in the public interest."

Thirty-eight members of Congress and a broad range of scientific and medical
organizations have joined Professor Craker in challenging the federal
government’s policy of blocking administrative channels and obstructing research
that could lead to the development of marijuana as a prescription medicine.
These organizations include the Lymphoma Foundation of America, the National
Association for Public Health Policy, the Multiple Sclerosis Foundation, as well
as several state medical and nurses’ associations.

Marijuana is the only Schedule I drug that DEA has prohibited from being
produced by private laboratories for scientific research. Other controlled
substances, including LSD, MDMA (also known as "Ecstasy"), heroin and cocaine,
are available to researchers from DEA-licensed private laboratories, such as the
one Professor Craker plans to establish.

In contrast, NIDA has remained scientists’ sole source of marijuana, despite
criticism over the agency’s refusal to make marijuana available for all
FDA-approved research into the plant’s potential medical value. The ACLU and
others point out that such research conflicts with NIDA’s mission to study the
harmful effects of drugs of abuse. In addition, researchers report that
marijuana available through NIDA is of low quality and variety and is not
optimized to meet FDA standards for prescription drug development.

Professor Craker’s proposed facility to grow high-quality medical marijuana
for research purposes will be funded by the Multidisciplinary Association for
Psychedelic Studies (MAPS), a non-profit pharmaceutical company with plans to
develop marijuana into a fully legal, prescription medication.

"For decades, we’ve been told by the politicians that marijuana has no proven
medical value while scientists have been denied the ability to prove otherwise,"
said Rick Doblin, Ph.D., president and founder of MAPS. "Hopefully, today’s
decision marks a shift towards science, not politics, guiding medicine in
America."

Despite federal prohibition, 12 states have enacted legislation protecting
patients who use medical marijuana with a physician’s recommendation from
prosecution under state law, and national polls consistently find that roughly
75 percent of Americans support the use of medical marijuana.

"Today’s ruling is an important step toward allowing medical marijuana
patients to get their medicine from a pharmacy just like everyone else," added
the ACLU’s Hopper. "That would clear up the controversies surrounding state
medical marijuana laws."

The ACLU is co-counsel in the case, In the Matter of Lyle Craker, with Julie
Carpenter at the Washington D.C. law firm Jenner & Block, LLP and is
assisted by Steptoe & Johnson, LLP.